Treace to Report First Quarter 2022 Financial Results on May 5, 2022

Rhea-AI Summary

Treace Medical Concepts (NasdaqGS: TMCI) announced it will release its financial results for the first quarter of 2022 on May 5, 2022, after market close. A conference call will be held at 4:30 p.m. ET to discuss these results. The company specializes in innovative surgical solutions for bunion deformities, notably the patented Lapiplasty® 3D Bunion Correction™ system. This system aims to address the root causes of bunions and facilitate recovery. The event will be accessible via a conference call and webcast on Treace's investor relations website.

Positive

• Company set to release Q1 2022 financial results, indicating transparency with investors.
• Continued innovation in bunion correction with patented Lapiplasty® system and new Adductoplasty™ system.

Negative

• None.

PONTE VEDRA, Fla., April 14, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today announced that it will release financial results for the first quarter of 2022 after the close of trading on Thursday, May 5, 2022. Company management will host a conference call to discuss financial results beginning at 4:30 p.m. ET.

Investors interested in listening to the conference call may do so by dialing (888) 708-0264 for domestic callers or (720) 405-2122 for international callers, followed by Conference ID: 7287077. A live and archived webcast of the event will be available on the Company’s investors relations website at https://investors.treace.com/.

About Treace Medical Concepts

Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion deformities and related midfoot correction. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction™ system – a combination of instruments, implants, and surgical methods designed to correct all 3 planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. Treace recently expanded its offering with the Adductoplasty™ Midfoot Correction System, designed for reproducible correction of the midfoot to provide further support to hallux valgus patients. For more information, please visit www.treace.com.

Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net 
(904) 373-5940

Investors:
Gilmartin Group
Lynn Lewis or Vivian Cervantes
IR@treace.net 

FAQ

When will Treace Medical Concepts (TMCI) release its Q1 2022 financial results?

Treace Medical Concepts will release its Q1 2022 financial results on May 5, 2022, after the market closes.

What time is the conference call for Treace Medical Concepts' Q1 2022 results?

The conference call for Treace Medical Concepts' Q1 2022 results is scheduled for 4:30 p.m. ET on May 5, 2022.

How can investors access the Treace Medical Concepts conference call?

Investors can access the Treace Medical Concepts conference call by dialing (888) 708-0264 for domestic or (720) 405-2122 for international calls, using Conference ID: 7287077.

What is Treace Medical Concepts' focus in the medical technology sector?

Treace Medical Concepts focuses on advancing surgical treatments for bunion deformities, utilizing innovative solutions like the Lapiplasty® system.